Durata Therapeutics
Durata Therapeutics was a clinical development stage company in the pharmaceutical industry which focused on the treatment of infections. On November 17, 2014, the company was acquired by Actavis (now Allergan) for $675 million.
| Industry | Pharmaceutical industry |
|---|---|
| Founded | 2009 |
| Defunct | November 17, 2014 |
| Fate | Acquired by Actavis (now Allergan) |
| Headquarters | Morristown, New Jersey |
History
On December 21, 2009, the company acquired Vicuron Pharmaceuticals and its drug candidate, dalbavancin, a long-acting semisynthetic lipoglycopeptide antibiotic, from Pfizer and commenced operations.[1]
On April 19, 2011, the company initiated Phase III studies of dalbavancin for intravenous (IV) treatment of acute bacterial skin and skin structure infections.[2]
In 2012, the company moved its global headquarters from Morristown to Chicago and received $2 million in tax credits.[3]
References
- "Newly Formed Durata Therapeutics Acquires Pfizer's Vicuron Subsidiary" (Press release). PR Newswire. December 21, 2009.
- "Durata Therapeutics Initiates Phase 3 Study of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections" (Press release). Business Wire. April 19, 2011.
- Frost, Peter (November 14, 2012). "Durata biotech moving headquarters to Chicago". Chicago Tribune.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.